An RNA test in development that confirms whether a patient has HCV within 40 minutes could enable diagnosis and prescribing treatment during a single office visit.
New tumor profiling papers stemming from prior clinical trials led to informative mutations in early-stage, ER+/HER2- breast cancer and lung squamous cell carcinoma.
The Wall Street Journal reports that some researchers are pinning their hopes to small, targeted clinical trials, while others argue large trials are still needed.
